Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. (NYSE: MRK) announced a deal Monday to buy Tilos Therapeutics. Only recently, the pharma giant agreed to buy Peloton Therapeutics in a deal valued at up to $2.2 billion. Merck struck an agreement to buy privately held Tilos, which develops therapies targeting the latent transforming growth factor — or TGT-beta — complex for treating cancer, fibrosis and autoimmune diseases, for up to $773 million, including an upfront payment as well as contingent milestone payments. "Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF-beta by binding to latency-associated peptide, with potential applications across a range of disease indications," Dean Li, senior vice president for discovery and translational medicine at Merck Research Laboratories, said in a statement.

First found on: And then on: 1 other references